Nektar Therapeutics - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NKTR Nasdaq 2830 www.nektar.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nektar Therapeutics

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Jul 2nd, 2025 2:15 pm
Upcoming Economic Data, Powell Comments Drive Premarket Losses for US Equity Futures - Jul 1st, 2025 7:09 am
Nektar Therapeutics Announces Pricing of $100 Million Public Offering - Jul 1st, 2025 5:17 am
Nektar Therapeutics Announces Proposed Public Offering - Jun 30th, 2025 2:01 pm
Why Nektar Therapeutics Stock Was Red-Hot Today - Jun 25th, 2025 4:45 pm
Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data - Jun 25th, 2025 10:20 am
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study - Jun 25th, 2025 9:30 am
Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment - Jun 24th, 2025 2:23 pm
Sector Update: Health Care Stocks Advance Late Afternoon - Jun 24th, 2025 2:03 pm
Sector Update: Health Care Stocks Higher in Afternoon Trading - Jun 24th, 2025 11:59 am
Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results - Jun 24th, 2025 8:54 am
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? - Jun 24th, 2025 8:40 am
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis - Jun 24th, 2025 5:30 am
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 - Jun 23rd, 2025 2:30 pm
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - May 14th, 2025 6:04 am
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - May 13th, 2025 3:00 pm
Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - May 13th, 2025 5:12 am
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - May 11th, 2025 7:39 am
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - May 9th, 2025 7:08 am
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - May 9th, 2025 1:46 am